This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
News

Transactions

Jun. 18, 2002

SAN DIEGO DRUG COMPANY NETS SECOND ROUND FUNDS

Favrille Inc. netted $16.9 million in its recent second-round financing. The deal was announced June 11. Sanderling Ventures led the round. De Novo Ventures, Indofin NV, Lotus BioScience Investment Holdings Limited, Forward Ventures and Alloy Ventures were the other investors.

        Favrille Inc. netted $16.9 million in its recent second-round financing. The deal was announced June 11.
        Sanderling Ventures led the round. De Novo Ventures, Indofin NV, Lotus BioScience Investment Holdings Limited, Forward Ventures and Alloy Ventures were the other investors.
        San Diego's Favrille is a biotechnology company that produces drugs for patients with cancer and other auto-immune diseases. The company targets the genes in each patient to create a drug targeted to the patient's specific needs.
        Palo Alto's
Cooley Godward represented Favrille in the deal. San Diego partner Frederick Muto led the deal team, comprising associates David Berger and Danielle Bersofsky.
        Paulette Taylor handled the deal in-house for Sanderling.
        - Stefanie Knapp

#299545

Stefanie Knapp

Daily Journal Staff Writer

For reprint rights or to order a copy of your photo:

Email Jeremy_Ellis@dailyjournal.com for prices.
Direct dial: 213-229-5424

Send a letter to the editor:

Email: letters@dailyjournal.com